Bard Associates’s Cellectar Biosciences CLRB Stock Holding History

Bard Associates’s Portfolio CLRB Stock Details CLRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-1	Closed	-$29K	–	166
2015 Q4	$29K	Hold	1	–	–	0.02%	153
2015 Q3	$77K	Hold	1	–	–	0.04%	151
2015 Q2	$124K	Hold	1	–	–	0.06%	158
2015 Q1	$134K	Hold	1	–	–	0.06%	155
2014 Q4	$133K	Hold	1	–	–	0.06%	159
2014 Q3	$95K	Buy	+1	New	+$86.3K	0.04%	159

Other funds holding CLRB

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WAM

Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Bard Associates's CLRB Position: Q1 2016 in Review

Bard Associates sold out of Cellectar Biosciences (CLRB) in Q1 2016, closing a stake of 1 share — an estimated $29K sold.

Bard Associates first reported a position in CLRB in Q3 2014 and held it in 6 quarters. The position peaked at $134K in Q1 2015. 4 funds tracked by Wall St. Rank hold CLRB as of Q1 2016.

Bard Associates reported no remaining Cellectar Biosciences position as of Q1 2016 after selling out during the quarter.
Bard Associates sold 1 Cellectar Biosciences share in Q1 2016, an estimated $29K.
Bard Associates first reported a position in Cellectar Biosciences in Q3 2014 and held it in 6 quarters.
Bard Associates's Cellectar Biosciences position peaked at $134K in Q1 2015.
4 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q1 2016.

Based on Bard Associates's 13F filing for Q1 2016, filed 12 May 2016.